CD14 Blockade Modulates Macrophage-Mediated Immunological Injury in a Translational Model of Reperfused ST-Segment Elevation Myocardial Infarction

Summary: These preclinical trials provide the first evidence of cluster of differentiation 14 (CD14) blockade with a murine analogue of atibuclimab, a CD14-neutralizing antibody, preventing secondary immunological exacerbation of cardiac injury in a translational mouse model of reperfused ST-segment...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Aascha A. D’Elia (nee Brown), PhD, Helen Kiriazis, PhD, Jason Bloom, MD, Jonathan Noonan, PhD, Ian Hsu, PhD, Gabriella E. Farrugia, PhD, Haoyun Fang, PhD, Stephanie Jansen, BVetSc, Natalia Carvajal, PhD, Crisdion Krstevski, PhD, Waled A. Shihata, PhD, Yow Keat Tham, PhD, Angela Vais, PhD, Camilla Cohen, PhD, Adam C. Parslow, PhD, Chad Johnson, PhD, Anita C. Thomas, PhD, Malathi S.I. Dona, PhD, Kyah Grigolon, BVetSc, Scott J.Y. Loh, BSc (Hons), Guy Krippner, PhD, David K. Wright, PhD, Bing H. Wang, PhD, Antonio Abbate, MD, PhD, Junedh Amrute, PhD, Kory Lavine, MD, PhD, Mark W. Appleby, PhD, David Crowe, PhD, Garry Redlich, DUniv, Brian W. Ziegelaar, PhD, Julie R. McMullen, PhD, David W. Greening, PhD, Alexander R. Pinto, PhD, David M. Kaye, MD, PhD, Daniel G. Donner, PhD
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2025-11-01
Serie:	JACC: Basic to Translational Science
Soggetti:	antibody therapy CD14 heart failure immunomodulation myocardial infarction
Accesso online:	http://www.sciencedirect.com/science/article/pii/S2452302X25003468
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!